Abstract

Central nervous system (CNS) metastases remain a significant problem in the management of patients with ALK -rearranged non-small cell lung cancer (NSCLC). The frequency of CNS involvement in ALK -positive tumors is extremely high; it approaches 25% in treatment naive patients (1) and rises to 50% in patients treated with crizotinib (2,3). Crizotinib was previously reported to have only minor intracranial activity (4), with poor CNS penetration suggested as the underlying mechanism (5).

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.